Last reviewed · How we verify
NCT05520281: ORPHYS
Short-term Psychodynamic Psychotherapy in Serious Physical Illness
NA trial testing Short-term psychodynamic psychotherapy for patients with serious physical illness (ORPHYS) in Malignant Neoplasm in 24 participants. Completed in 6 August 2025.
6 August 2025
Quick facts
| Lead sponsor | Universitätsklinikum Hamburg-Eppendorf |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 15 September 2022 |
| Primary completion | 6 August 2025 |
| Estimated completion | 6 August 2025 |
| Sites | 4 locations across Germany |
Drugs / interventions tested
- Short-term psychodynamic psychotherapy for patients with serious physical illness (ORPHYS)
Conditions studied
- Malignant Neoplasm — all drugs for Malignant Neoplasm →
- Carcinoma — all drugs for Carcinoma →
- Palliative Care — all drugs for Palliative Care →
Sponsor
Universitätsklinikum Hamburg-Eppendorf — full company profile →
Who can join
18 and older, any sex, with Malignant Neoplasm or Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Life-threatening physical illness may powerfully re-activate existential conflict. There is little evidence to date on the effectiveness of relationship-focused therapies in this patient group.The aim of this study is to pilot a psychodynamic treatment for patients with advanced cancer and high psychological distress.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Existential distress in advanced cancer: study protocol of a pragmatic randomized controlled trial of a short-term psychodynamic therapy (ORPHYS) compared to usual psycho-oncological treatment (TAU).
Philipp R, Walbaum C, Bokemeyer C, Dinger U, et al · · 2026 · PMID 42098804 · DOI 10.1186/s13063-026-09744-x
Verify or expand the search:
- PubMed search for NCT05520281
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malignant Neoplasm
Currently open trials in the same condition.
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
- NCT07252739 — KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
- NCT07247110 — A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) · Phase 1 · recruiting
- NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting
Other Universitätsklinikum Hamburg-Eppendorf trials
Trials by the same sponsor.
- NCT07443384 — Complications Associated With Radiofrequency Microneedling in Dermatology: a Delphi Consensus · not yet recruiting
- NCT07385092 — Continuous Vital Sign Monitoring Versus Routine Spot-checks in Patients After Non-cardiac Surgery · NA · recruiting
- NCT07009522 — Hamburg Emotion Awareness and Regulation Group Training for Autistic Adolescents (HEART) · EARLY_PHASE1 · not yet recruiting
- NCT07115394 — EEG Measurements to Capture DBS-induced Electric Potentials · recruiting
- NCT06955884 — Patient Experience of Transoral Versus Transnasal Awake Tracheal Intubation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05520281 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitätsklinikum Hamburg-Eppendorf
- Last refreshed: 15 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05520281.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing